Determination of Regulatory Review Period for Purposes of Patent Extension; ZILMAX

Summary

The Food and Drug Administration (FDA) has determined the regulatory review period for ZILMAX, a patent extension, and is publishing this notice as required by law. The FDA made this determination due to a submission to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent for the animal drug product ZILMAX.